This effect is capable of manifesting itself across the four different perspectives described below:
- 1st person - The most common form of perspective can be described as the normal experience of perceiving a hallucination from the person's everyday self and body.
- 2nd person - This perspective can be described as the experience of perceiving a hallucination from the viewpoint of an external source of consciousness, such as another person, an animal, or an inanimate object.
- 3rd person - This perspective can be described as an out-of-body experience where a person's viewpoint is floating above, below, behind, or in front of their physical body.
- 4th person - The least common form of perspective can be described as the experience of perceiving a hallucination from multiple or even seemingly infinite viewpoints and angles simultaneously.
Perspective hallucinations are often accompanied by other coinciding effects such as delirium, and memory suppression. They are most commonly induced under the influence of heavy dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and deliriants.
Compounds within our psychoactive substance index which may cause this effect include:
- Amanita muscaria
Anecdotal reports which describe this effect within our experience index include:
- Experience: 25mg 2C-E (oral) - A mindblowing experience
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:40mg - Brothermind and the Forest's Hand
- Experience:DMT (unknown dose, smoked) - It felt like I was on rails the whole time
- Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death
- Responsible use
- Subjective effects index
- Perspective distortions
- Deliriants - Subjective effects
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Dillon, P (2003). "Patterns of use and harms associated with non-medical ketamine use". Drug and Alcohol Dependence. 69 (1): 23–28. doi:10.1016/S0376-8716(02)00243-0. ISSN 0376-8716.
- Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS (REVIEW). PHARMACIA, 64(1), 41-42. http://bsphs.org/wp-content/uploads/2017/04/Angelova.pdf
- Jansen, K.L.R. (1990). "Neuroscience and the Near-Death Experience: Roles for the NMSA-PCP receptor, the sigma receptor and the endopsychosins". Medical Hypotheses. 31 (1): 25–29. doi:10.1016/0306-9877(90)90048-J. ISSN 0306-9877.
- Rumpf K, Pedeck J, Teuteberg H. Munchhoff W. Nolte H. Dream-like experiences during brief anaesthesia with ketamine. thiopental and propanidid. p 161 in Ketamine (H Kreuscher. ed.) Springer-Verlag. Berlin, 1969.
- Siegel R K. Phencyclidine and ketamine intoxication: a study of recreational users. p 119 in Phencyclidine Abuse: An Appraisal (R C Peterson. R C Stillman. eds.). National Institute on Drug Abuse Research Monograph 21. NIDA. Rockville. Maryland, 1978.
- Wilkins, Leanne K.; Girard, Todd A.; Cheyne, J. Allan (2011). "Ketamine as a primary predictor of out-of-body experiences associated with multiple substance use". Consciousness and Cognition. 20 (3): 943–950. doi:10.1016/j.concog.2011.01.005. ISSN 1053-8100.
- Przyby, A. (n.d.). A Philosophical Journey into the Heart of the Psychedelic Dream. Chicago, IL: University of Chicago. Retrieved February 24, 2018, from http://midwayreview.uchicago.edu/a/8/3/przybyl/przybyl.pdf